Edwards Lifesciences (EW) Misses Q4 EPS by 4c, Beats on Revenue; Offers Q1 Guidance
Tweet
Share
E-mail
Get Alerts EW Hot Sheet
Price: $85.88 -1.69%
Revenue Growth %: +11.1%
Financial Fact:
Income before provision for income taxes: 185.2M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +11.1%
Financial Fact:
Income before provision for income taxes: 185.2M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.58, $0.04 worse than the analyst estimate of $0.62. Revenue for the quarter came in at $1.57 billion versus the consensus estimate of $1.55 billion.
GUIDANCE:
Edwards Lifesciences sees Q1 2026 EPS of $0.70-$0.76, versus the consensus of $0.69. Edwards Lifesciences sees Q1 2026 revenue of $1.55-1.63 billion, versus the consensus of $1.57 billion.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- ZenaTech raises Plurilock Security stake to 12% with new share purchase
- Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
